Relationship between uncontrolled risk factors and C-reactive protein levels in patients receiving standard or intensive statin therapy for acute coronary syndromes in the PROVE IT-TIMI 22 trial.
暂无分享,去创建一个
Nader Rifai | Christopher P Cannon | David A Morrow | Paul M Ridker | A. Skene | P. Ridker | E. Braunwald | C. Cannon | A. Kirtane | N. Rifai | D. Morrow | Richard Cairns | C. McCabe | C. Gibson | K. Ray | Kausik K Ray | Ajay J Kirtane | C Michael Gibson | Eugene Braunwald | Richard Cairns | Carolyn H McCabe | Allan M Skene | Prove It-Timi Investigators
[1] P. Ridker,et al. Relative efficacy of atorvastatin 80 mg and pravastatin 40 mg in achieving the dual goals of low-density lipoprotein cholesterol <70 mg/dl and C-reactive protein <2 mg/l: an analysis of the PROVE-IT TIMI-22 trial. , 2005, Journal of the American College of Cardiology.
[2] J. Manson,et al. Effect of Intensive Glycemic Control on Levels of Markers of Inflammation in Type 1 Diabetes Mellitus in the Diabetes Control and Complications Trial , 2005, Circulation.
[3] A. Moss,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[4] B. Cohen,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[5] Paul Schoenhagen,et al. Statin therapy, LDL cholesterol, C-reactive protein, and coronary artery disease. , 2005, The New England journal of medicine.
[6] G. Hitman,et al. Association between fasting glucose and C-reactive protein in middle-aged subjects. , 2005, Diabetic medicine : a journal of the British Diabetic Association.
[7] M. Pfeffer,et al. C-reactive protein levels and outcomes after statin therapy. , 2005, The New England journal of medicine.
[8] J. Griffith,et al. Comparison of the Atkins, Ornish, Weight Watchers, and Zone diets for weight loss and heart disease risk reduction: a randomized trial. , 2005, JAMA.
[9] A. Kitabatake,et al. Can Exercise Training With Weight Loss Lower Serum C-Reactive Protein Levels? , 2004, Arteriosclerosis, thrombosis, and vascular biology.
[10] R. Marfella,et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. , 2004, JAMA.
[11] B. Nicklas,et al. Reductions in plasma cytokine levels with weight loss improve insulin sensitivity in overweight and obese postmenopausal women. , 2004, Diabetes care.
[12] K. Shimada,et al. Early intervention with atorvastatin modulates TH1/TH2 imbalance in patients with acute coronary syndrome: from bedside to bench. , 2004, Circulation.
[13] F. Fabris,et al. Body fat and C-reactive protein levels in healthy non-obese men. , 2004, Nutrition, metabolism, and cardiovascular diseases : NMCD.
[14] C. Lavie,et al. Reduction in C-reactive protein through cardiac rehabilitation and exercise training. , 2004, Journal of the American College of Cardiology.
[15] C. Roberts,et al. Effect of diet and exercise intervention on inflammatory and adhesion molecules in postmenopausal women on hormone replacement therapy and at risk for coronary artery disease. , 2004, Metabolism: clinical and experimental.
[16] A. Jardine,et al. Fluvastatin inhibits raft dependent Fcγ receptor signalling in human monocytes , 2004 .
[17] Tzung-Dau Wang,et al. Effects of rosiglitazone on endothelial function, C-reactive protein, and components of the metabolic syndrome in nondiabetic patients with the metabolic syndrome. , 2004, The American journal of cardiology.
[18] Thomas Weber,et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. , 2004, The New England journal of medicine.
[19] A. Jardine,et al. Fluvastatin inhibits raft dependent Fcgamma receptor signalling in human monocytes. , 2004, Atherosclerosis.
[20] Tzung-Dau Wang,et al. Efficacy of fenofibrate and simvastatin on endothelial function and inflammatory markers in patients with combined hyperlipidemia: relations with baseline lipid profiles. , 2003, Atherosclerosis.
[21] W. Koenig,et al. Independent association of various smoking characteristics with markers of systemic inflammation in men. Results from a representative sample of the general population (MONICA Augsburg Survey 1994/95). , 2003, European heart journal.
[22] P. Sager,et al. Effect of Ezetimibe Coadministered With Atorvastatin in 628 Patients With Primary Hypercholesterolemia: A Prospective, Randomized, Double-Blind Trial , 2003, Circulation.
[23] Nancy R Cook,et al. C-Reactive Protein, the Metabolic Syndrome, and Risk of Incident Cardiovascular Events: An 8-Year Follow-Up of 14 719 Initially Healthy American Women , 2003, Circulation.
[24] J. Kampert,et al. Associations Between Cardiorespiratory Fitness and C-Reactive Protein in Men , 2002, Arteriosclerosis, thrombosis, and vascular biology.
[25] S. Haffner,et al. Effect of Rosiglitazone Treatment on Nontraditional Markers of Cardiovascular Disease in Patients With Type 2 Diabetes Mellitus , 2002, Circulation.
[26] Deepak L. Bhatt,et al. Need to test the arterial inflammation hypothesis. , 2002, Circulation.
[27] D. Mikhailidis,et al. Effect of Ciprofibrate on C-Reactive Protein and Fibrinogen Levels , 2002, Angiology.
[28] E. Poehlman,et al. Weight Loss Reduces C-Reactive Protein Levels in Obese Postmenopausal Women , 2002, Circulation.
[29] N Rifai,et al. Effect of statin therapy on C-reactive protein levels: the pravastatin inflammation/CRP evaluation (PRINCE): a randomized trial and cohort study. , 2001, JAMA.
[30] U. Laufs,et al. Targeting Rho in cardiovascular disease. , 2000, Circulation research.
[31] P. Ridker,et al. Survey of C-reactive protein and cardiovascular risk factors in apparently healthy men. , 1999, The American journal of cardiology.
[32] G. Shen,et al. Influence of glycation on LDL-induced generation of fibrinolytic regulators in vascular endothelial cells. , 1998, Arteriosclerosis, thrombosis, and vascular biology.
[33] U. Laufs,et al. Upregulation of endothelial nitric oxide synthase by HMG CoA reductase inhibitors. , 1998, Circulation.
[34] P. Ridker,et al. Inflammation, aspirin, and the risk of cardiovascular disease in apparently healthy men. , 1997, The New England journal of medicine.
[35] S. Thompson,et al. Production of C-reactive protein and risk of coronary events in stable and unstable angina , 1997, The Lancet.